SIB-1757 is a drug used in scientific research which was one of the first compounds developed that acts as a selective
antagonist for the
metabotropic glutamate receptor subtype
mGluR5.[1] It has anti-
hyperalgesia effects in animals.[2] SIB-1757 along with other mGluR5 antagonists has been shown to have neuroprotective and hepatoprotective effects,[3][4] and it is also used to study the role of the mGluR5 receptor in brain development.[5]
References
^Varney MA, Cosford ND, Jachec C, Rao SP, Sacaan A, Lin FF, Bleicher L, Santori EM, Flor PJ, Allgeier H, Gasparini F, Kuhn R, Hess SD, Veliçelebi G, Johnson EC (July 1999). "SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5". The Journal of Pharmacology and Experimental Therapeutics. 290 (1): 170–81.
PMID10381773.
^Dogrul A, Ossipov MH, Lai J, Malan TP, Porreca F (October 2000). "Peripheral and spinal antihyperalgesic activity of SIB-1757, a metabotropic glutamate receptor (mGLUR(5)) antagonist, in experimental neuropathic pain in rats". Neuroscience Letters. 292 (2): 115–8.
doi:
10.1016/S0304-3940(00)01458-0.
PMID10998562.
S2CID7718378.